Molecular 'portraits' of tumours match patients with trials in everyday clinical practice

November 8, 2012 in Cancer

Researchers in France are taking advantage of the progress in genetic and molecular profiling to analyse the make-up of individual cancer patients' tumours and, using this information, assign them to particular treatments and phase I clinical trials—an approach that could become part of everyday clinical practice.

In research presented at the 24th EORTC-NCI-AACR Symposium on and in Dublin, Ireland, today, Dr Christophe Massard, a medical oncologist and senior consultant in the early drug development unit at the Institut Gustave Roussy in Villejuif, France, describes how he and his colleagues have successfully incorporated "molecular triaging" into their phase I clinical trial unit, with results of ' molecular analyses being made available within three weeks of a sample being taken.

"Advances in our ability to characterise the genomic changes that drive an individual patient's tumour have led to successes in phase I trials that select patients on the basis of the molecular make-up of their tumours," said Dr Massard. "So we set up a prospective molecular triage trial in which fresh tumour biopsies were taken from patients with advanced cancer referred to our phase I unit. The study aims at offering patients a molecular portrait of their tumour. This allows us to rationally direct those patients to the relevant phase I trial, i.e. the one with an anti-cancer drug targeting the tumour's molecular driver that has been identified by the analysis."

The trial is called MOSCATO 01 (MOlecular Screening for and Optimisation) and since October 2011 more than 120 patients have been enrolled. Tumour samples were taken with the aid of (CT) or ultra-sound guidance. The researchers analysed the biopsies using comparative genome hybridisation (CGH) to identify changes in the DNA of the tumour, such as mutations, gene deletions or amplifications, or other , and results were available within three weeks. An expert panel of scientists and clinicians reviewed the results to decide on the biological significance of the molecular changes and then referred the patients to the relevant phase I trial where it was available.

Over 95% of patients agreed to join the MOSCATO trial. Molecular analysis has proved feasible in more than 85% of patients, molecular alterations have been detected in half of them and 30% of patients have been allocated so far to a specific trial on the basis of the analysis.

"The most important findings at the moment are that this approach is feasible in the context of daily practice, and the patients are very keen to participate to this programme. A hundred patients were enrolled in seven months. They intuitively know that rational choice of their therapies is key to their future. For some patients, the results of the analyses changed the phase I trials and treatments for which they were being considered," said Dr Massard.

The researchers are continuing the trial and aim to enrol a total of 900 patients. Dr Massard says the approach could be used by other cancer centres but it requires a good, multidisciplinary team, including clinicians, interventional radiologists, pathologists, biologists, bioinformaticians and statisticians, who are available to meet on a regular basis to discuss the results of the molecular analyses.

Professor Stefan Sleijfer, the scientific chair of the EORTC-NCI-AACR Symposium, from Erasmus University Medical Centre (The Netherlands), commented: "This study is interesting because it shows the feasibility of performing complex molecular characterisation of tumours in daily . Such approaches are key to reaching a more personalised treatment approach for ."

Examples of targeted anti- where phase I trials have demonstrated the success of selecting patients on the basis of the molecular make-up of their tumour include: olaparib, a PARP inhibitor, which was used successfully in phase I trials against tumours involving mutations in the BRCA 1/2 genes; vemurafenib used in melanomas with mutations in the BRAF gene; crizotinib in non-small cell lung cancers with translocations in the ALK gene; and vismodegib used in basal cell carcinoma with mutations in the SMO gene.

More information: Abstract no: 612. Poster session, Phase I trials, 09.00 hrs, Friday 9 November.

Provided by ECCO-the European CanCer Organisation

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

American cancer society celebrates 100 years of progress

(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.

Cancer created 47 minutes ago | popularity not rated yet | comments 0

CT detects twice as many lung cancers as X-ray at initial screening exam

National Lung Screening Trial (NLST) investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography (LDCT) versus chest X-ray (CXR) screening previously reported in the ...

Cancer created 1 hour ago | popularity not rated yet | comments 0

Research offers promising new approach to treatment of lung cancer

Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...

Cancer created 4 hours ago | popularity not rated yet | comments 0 | with audio podcast

Study details genes that control whether tumors adapt or die when faced with p53 activating drugs

When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...

Cancer created 4 hours ago | popularity not rated yet | comments 0 | with audio podcast

Small increase in cancer risk following CT scans in childhood and adolescence

Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.

Cancer created 8 hours ago | popularity not rated yet | comments 0


Systematic screening of med adherence will ID barriers

(HealthDay)—Implementation of systematic monitoring for medication adherence will allow for identification of barriers to adherence and tailoring of interventions, according to a viewpoint piece published ...

FDA panel backs experimental Merck insomnia drug

(AP)—A federal panel of medical experts says that an experimental insomnia drug from Merck & Co Inc. appears safe and effective, despite evidence from company trials that the pill can cause daytime sleepiness and difficulty ...

Having both migraines, depression may mean smaller brain

(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.

Brain can be trained in compassion, study shows

Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.

Swine flu pandemic of 2009 more deadly for younger adults, study finds

As the world prepares for what may be the next pandemic strain of influenza virus, in the H7N9 bird flu, a new UC Irvine study reveals that the 2009 H1N1 swine flu pandemic was deadliest for people under the age of 65, while ...

'Boys will be boys' in US, but not in Asia

A new study shows there is a gender gap when it comes to behavior and self-control in American young children – one that does not appear to exist in children in Asia.